Pluri is an Israeli biotechnology company built around a proprietary 3D cell expansion platform that uses synthetic scaffolds and bioreactors to grow large quantities of cells efficiently. Pluri applies this platform across several industries, though its only active revenue business today is PluriCDMO, a contract development and manufacturing organization launched in January 2024. PluriCDMO provides outsourced cell therapy manufacturing services to pharma and biotech companies across the development lifecycle — from preclinical through commercial supply — using a GMP-certified facility in Haifa, Israel. Beyond CDMO services, Pluri is developing a pipeline of placenta-derived cell therapy candidates under the Pluri Health umbrella, including PLX-PAD (targeting inflammatory and musculoskeletal conditions) and PLX-R18 (targeting hematopoietic conditions and acute radiation syndrome), neither of which is commercially approved. Pluri also holds stakes in several early-stage subsidiaries and joint ventures that apply its cell expansion platform to food and agriculture: Ever After Foods (~69% owned) develops B2B cultivated meat production systems and sells bioreactor infrastructure to food producers; Coffeesai (wholly owned) and Kokomodo (~79% owned) are developing cell-cultured coffee and cacao, respectively, both at proof-of-concept stage. Pluri's longer-term model aims to monetize the platform through technology licensing, royalties, and product sales across these verticals, supplemented by grant and contract funding for R&D.